An Overview of HER2 Alterations in NSCLC and Implications for Treatment
Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing methods such as IHC and NGS.
- Can you provide an overview of different HER2 alterations in NSCLC? What are the key differences between HER2 overexpression and HER2 mutations in NSCLC, in terms of biology and how we detect them? How do these distinctions impact our approach to patient care?
- How do prognoses and survival outcomes differ for patients with HER2-overexpressing NSCLC vs those with HER2-mutated NSCLC?
- Can you walk us through your biomarker testing practices in NSCLC, particularly for identifying HER2 overexpression vs HER2 mutations? What are the challenges and considerations specific to each testing approach in NSCLC (IHC vs NGS testing)?
- How do you balance the need for comprehensive biomarker testing with the limitations of tissue availability?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
